A Study to Assess How Food Affects the Safety and Pharmacokinetics of Galicaftor and Navocaftor

Completed · Phase 1

Conditions studied: Healthy Volunteers

In brief

Cystic Fibrosis (CF) is a rare, life-threatening, genetic disease that affects the lungs and digestive system, significantly impairing the quality of life, with those affected having a median age of death at 40. The objectives of this study are to assess the effect of food on the safety and pharmacokinetics of navocaftor and galicaftor.

Key facts

Study ID
NCT05538585
Run by
AbbVie
People needed
24
Starts
2022-09-27
Expected to finish
2022-12-21
Last updated by the study team
2023-01-17

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.